Activity profile of an FDA-approved compound library against Schistosoma mansoni

PLoS Neglected Tropical Diseases

Volumn 9, Issue 7, 2015, Pages 1-15

  Panic, Gordana ^a,b   Vargas, Mireille ^a,b   Scandale, Ivan ^c   Keiser, Jennifer ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DORAMECTIN; FENDILINE; FLUNARIZINE; LOMERIZINE; MANIDIPINE; MENADIONE; METITEPINE; NICARDIPINE; OXETACAINE; PIMOZIDE; ANTISCHISTOSOMAL AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HELMINTHIASIS; IC50; MOUSE; NONHUMAN; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SCORING SYSTEM; ANIMAL; DRUG EFFECTS; FOOD AND DRUG ADMINISTRATION; UNITED STATES;

ANIMALS; FEMALE; INHIBITORY CONCENTRATION 50; MICE; PARASITIC SENSITIVITY TESTS; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SCHISTOSOMICIDES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84938585442     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003962     Document Type: Article

References (46)

1. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012; 380: 2197–2223.
2. Engels D, Chitsulo L, Montresor A, Savioli L. The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Trop. 2002; 82: 139–146.PMID: 12020886
3. Ezeamama AE, Friedman JF, Acosta LP, Bellinger DC, Langdon GC, Manalo DL, et al. Helminth infection and cognitive impairment among Filipino children. Am J Trop Med Hyg. 2005; 72: 540–548.PMID: 15891127
4. Gryseels B. Schistosomiasis. Infect Dis Clin North Am. 2012; 26: 383–397. doi: 10.1016/j.idc.2012.03.004PMID: 22632645
5. Taylor Myra. Global trends in schistosomiasis control. Bull World Health Organ. 2008; 86: 737–816.
6. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, Sachs JD. Incorporating a rapidimpact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med. 2006; 3: e102.PMID: 16435908
7. Webster JP, Molyneux DH, Hotez PJ, Fenwick A. The contribution of mass drug administration to global health: past, present and future. Philos Trans R Soc Lond B Biol Sci. 2014; 369: 20130434. doi: 10.1098/rstb.2013.0434PMID: 24821920
8. Knopp S, Becker SL, Ingram KJ, Keiser J, Utzinger J. Diagnosis and treatment of schistosomiasis in children in the era of intensified control. Expert Rev Anti Infect Ther. 2013; 11: 1237–1258. doi: 10.1586/14787210.2013.844066PMID: 24127662
9. Fenwick A, Savioli L, Engels D, Robert Bergquist N, Todd MH. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol. 2003; 19: 509–515.PMID: 14580962
10. Wang W, Wang L, Liang Y-S. Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res. 2012; 111: 1871–1877. doi: 10.1007/s00436-012-3151-zPMID: 23052781
11. Pedrique B, Strub-Wourgaft N, Some C, Olliaro P, Trouiller P, Ford N, et al. The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment. Lancet Glob Health. 2013; 1: e371–e379. doi: 10.1016/S2214-109X(13)70078-0PMID: 25104602
12. Panic G, Duthaler U, Speich B, Keiser J. Repurposing drugs for the treatment and control of helminth infections. Int J Parasitol Drugs Drug Resist. 2014; 4: 185–200. doi: 10.1016/j.ijpddr.2014.07.002PMID: 25516827
13. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3: 673–683.PMID: 15286734
14. Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med. 2011; 57: 153–160. doi: 10.4103/0022-3859.81870PMID: 21654146
15. Abdulla M-H, Ruelas DS, Wolff B, Snedecor J, Lim K-C, Xu F, et al. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl Trop Dis. 2009; 3: e478. doi: 10.1371/journal.pntd.0000478PMID: 19597541
16. Ingram-Sieber K, Cowan N, Panic G, Vargas M, Mansour NR, Bickle QD, et al. Orally active antischistosomal early leads identified from the open access Malaria Box. PLoS Negl Trop Dis. 2014; 8: e2610. doi: 10.1371/journal.pntd.0002610PMID: 24416463
17. Neves BJ, Braga RC, Bezerra JCB, Cravo PVL, Andrade CH. In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni. PLoS Negl Trop Dis. 2015; 9: e3435. doi: 10.1371/journal.pntd.0003435PMID: 25569258
18. Keiser J. In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology. 2010; 137: 589–603. doi: 10.1017/S0031182009991739PMID: 19961653
19. Galdino da Rocha Pitta M, Galdino da Rocha Pitta M, Jesus Barreto de Melo Rego M, Lins Galdino S. The evolution of drugs on Schistosoma treatment: looking to the past to improve the future. Mini-Rev Med Chem. 2013; 13: 493–508.PMID: 23373654
20. Keiser J. Antimalarials in the treatment of schistosomiasis. Curr Pharm Des. 2012;
21. Andrews KT, Fisher G, Skinner-Adams TS. Drug repurposing and human parasitic protozoan diseases. Int J Parasitol Drugs Drug Resist. 2014; 4: 95–111. doi: 10.1016/j.ijpddr.2014.02.002PMID: 25057459
22. Protasio AV, Tsai IJ, Babbage A, Nichol S, Hunt M, Aslett MA, et al. A systematically improved high quality genome and transcriptome of the human blood fluke Schistosoma mansoni. PLoS Negl Trop Dis. 2012; 6: e1455. doi: 10.1371/journal.pntd.0001455PMID: 22253936
23. Taman A, El-Beshbishi S, El-Tantawy N, El-Hawary A, Azab M. Evaluation of the in vivo effect of ivermectin on Schistosoma mansoni in experimentally-infected mice. J Coast Life Med. 2014; 2: 817–23.
24. Whitworth JA, Morgan D, Maude GH, McNicholas AM, Taylor DW. A field study of the effect of ivermectin on intestinal helminths in man. Trans R Soc Trop Med Hyg. 1991; 85: 232–234.PMID: 1909471
25. Lumaret J-P, Errouissi F, Floate K, Rombke J, Wardhaugh K. A review on the toxicity and non-target effects of macrocyclic lactones in terrestrial and aquatic environments. Curr Pharm Biotechnol. 2012; 13: 1004–1060.PMID: 22039795
26. Attah SK, Kataliko K, Mutro MN, Kpawor M, Opuku NO, Kanza E. Effect of a single dose of 8 mg moxidectin or 150 μg/kg ivermectin on intestinal helminths in participants of a clinical trial conducted in Northeast DRC, Liberia and Ghana. New Orleans, USA: The America Journal of Tropical Medicine and Hygiene; 2014. http://www.astmh.org/AM/Template.cfm?Section=Abstracts_and_Education1&Template=/CM/ContentDisplay.cfm&ContentID=6128
27. WHO. Model Lists of Essential Medicines. In: World Health Organization [Internet]. Oct 2013 [cited 3 Mar 2015]. http://www.who.int/medicines/publications/essentialmedicines/en/
28. Fukutomi Y, Maeda Y, Makino M. Apoptosis-inducing activity of clofazimine in macrophages. Antimicrob Agents Chemother. 2011; 55: 4000–4005. doi: 10.1128/AAC.00434-11PMID: 21690278
29. Ren YR, Pan F, Parvez S, Fleig A, Chong CR, Xu J, et al. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS ONE. 2008; 3: e4009. doi: 10.1371/journal.pone.0004009PMID: 19104661
30. van Rensburg CE, Gatner EM, Imkamp FM, Anderson R. Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Antimicrob Agents Chemother. 1982; 21: 693–697.PMID: 7049077
31. Bellera CL, Balcazar DE, Vanrell MC, Casassa AF, Palestro PH, Gavernet L, et al. Computer-guided drug repurposing: Identification of trypanocidal activity of clofazimine, benidipine and saquinavir. Eur J Med Chem. 2015; 93: 338–348. doi: 10.1016/j.ejmech.2015.01.065PMID: 25707014
32. WHO. Use of clofazimine for treating ENL reactions in leprosy. In: World Health Organization [Internet]. 2015 [cited 3 Mar 2015]. http://www.who.int/lep/mdt/clofazimine/en/
33. Allan D, Payares G, Evans WH. The phospholipid and fatty acid composition of Schistosoma mansoni and of its purified tegumental membranes. Mol Biochem Parasitol. 1987; 23: 123–128.PMID: 3574354
34. Bansal D, Bhatti HS, Sehgal R. Role of cholesterol in parasitic infections. Lipids Health Dis. 2005; 4: 10.PMID: 15882457
35. Brouwers JFHM, Smeenk IMB, van Golde LMG, Tielens AGM. The incorporation, modification and turnover of fatty acids in adult Schistosoma mansoni. Mol Biochem Parasitol. 1997; 88: 175–185.PMID: 9274878
36. Tallima H, Hamada M, El Ridi R. Evaluation of cholesterol content and impact on antigen exposure in the outer lipid bilayer of adult schistosomes. Parasitology. 2007; 134: 1775–1783.PMID: 17617933
37. Rojo-Arreola L, Long T, Asarnow D, Suzuki BM, Singh R, Caffrey CR. Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis. Keiser J, editor. PLoS ONE. 2014; 9: e87594. doi: 10.1371/journal.pone.0087594PMID: 24489942
38. Chan JD, Agbedanu PN, Zamanian M, Gruba SM, Haynes CL, Day TA, et al. “Death and Axes”: Unexpected Ca2+ entry phenologs predict new anti-schistosomal agents. PLoS Pathog. 2014; 10: e1003942. doi: 10.1371/journal.ppat.1003942PMID: 24586156
39. Silva-Moraes V, Couto FFB, Vasconcelos MM, Araújo N, Coelho PMZ, Katz N, et al. Antischistosomal activity of a calcium channel antagonist on schistosomula and adult Schistosoma mansoni worms. Mem Inst Oswaldo Cruz. 2013; 108: 600–604.PMID: 23903976
40. Banno K, Iida M, Yanokura M, Irie H, Masuda K, Kobayashi Y, et al. Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer. Sci World J. 2015; 2015: e341362.
41. Gieseler F. Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. Thromb Haemost. 2008; 99: 1001–1007. doi: 10.1160/TH08-01-0009PMID: 18521500
42. Nwaka S, Hudson A. Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov. 2006; 5: 941–955.PMID: 17080030
43. Adverse Reaction Information Unit. Status of terfenadine-containing drugs in Canada [Internet]. Health Canada; 2001 Feb. http://publications.gc.ca/collections/Collection/H30-12-18-2001E.pdf
44. Gupta SC, Sung B, Prasad S, Webb LJ, Aggarwal BB. Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci. 2013; 34: 508–517. doi: 10.1016/j.tips.2013.06.005PMID: 23928289
45. Nix DE, Adam RD, Auclair B, Krueger TS, Godo PG, Peloquin CA. Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis. 2004; 84: 365–373.PMID: 15525560
46. Gokbulut C, Nolan AM, Mckellar QA. Plasma pharmacokinetics and faecal excretion of ivermectin, doramectin and moxidectin following oral administration in horses. Equine Vet J. 2001; 33: 494–498.PMID: 11558745